Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Kim J-, Lin C, Stavre Z, Greenblatt MB, Shim J-. Osteoblast-Osteoclast Communication and Bone Homeostasis. Cells. 2020;9(9).

Borczuk AC, Salvatore SP, Seshan SV, Patel SS, Bussel JB, Mostyka M, et al. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Mod Pathol. 2020;33(11):2156-2168.

Khorrami M, Prasanna P, Gupta A, Patil P, Velu PD, Thawani R, et al. Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer. Cancer Immunol Res. 2020;8(1):108-119.

Zhang S, Chiang GC, Knapp JM, Zecca CM, He D, Ramakrishna R, et al. Grading meningiomas utilizing multiparametric MRI with inclusion of susceptibility weighted imaging and quantitative susceptibility mapping. J Neuroradiol. 2020;47(4):272-277.

Todoric J, Di Caro G, Reibe S, Henstridge DC, Green CR, Vrbanac A, et al. Fructose stimulated de novo lipogenesis is promoted by inflammation. Nat Metab. 2020;2(10):1034-1045.

Lam HC, Baglini CV, Lope AL, Parkhitko AA, Liu H-, Alesi N, et al. Correction: p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis. Cancer Res. 2020;80(23):5424.

Haney NM, Faisal FA, Lu J, Guedes LB, Reuter VE, Scher HI, et al. Loss with Negative Status is Associated with Lethal Disease after Radical Prostatectomy. J Urol. 2020;203(2):344-350.

Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D, et al. TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. Cell. 2020;182(2):297-316.e27.

Armache A, Yang S, de Paz AM, Robbins LE, Durmaz C, Cheong JQ, et al. Histone H3.3 phosphorylation amplifies stimulation-induced transcription. Nature. 2020;583(7818):852-857.

Sangiorgio VF, Geyer JT, Margolskee E, Al-Kawaaz M, Mathew S, Tam W, et al. Myeloid neoplasms with isolated del(5q) and V617F mutation: a "grey zone" combination of myelodysplastic and myeloproliferative features? Haematologica. 2020;105(6):e276-e279.